Costliest Medicare drugs more than tripled in price since entering market: report

The 25 drugs that accounted for the highest Medicare Part D spending in 2021 more than tripled in price since they first entered the market, according to a new report from AARP.

Why it matters: The report comes just weeks before the Biden administration is to announce the first 10 Medicare Part D drugs that will be considered for price negotiations under the Inflation Reduction Act, on Sept. 1.